Moreover, a subgroup of anti-PAD4 antibodies that cross react with PAD3 (anti-PAD3/4 antibodies) is associated with the most severe and progressive joint disease and increased risk of interstitial lung disease (ILD) (16–19). Here, PADI3 is linked to arthropathy.